Forside  

Referanser

Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm
  • Engelsk tittel -
  • Versjon - 5. utgave
  • Status - Publisert
  • IS-nr - IS-2644
  • ISBN - 978-82-8081-505-7
  • DOI -
  • Revisjonsdato - 20.06.2017
  • Neste revisjon -
  • Publikasjonsdato - 11.08.2017
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
  1. Nasjonalt kvalitetsregister for tykk- og endetarmskreft. Årsrapport 2015. Oslo: Kreftregisteret; 2016. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2016/arsrapport-2015-tykk--og-endetarmskreft.pdf
  2. Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol 2015;54(10):1714-22.
  3. Gaard M, Tveit KM, Hafstad A. Kreftkirurgi i Norge. Oslo: Helsedirektoratet; 2015. IS-2284. Tilgjengelig fra: https://helsedirektoratet.no/Documents/Nyheter/IS-2284%20Rapport%20om%20kreftkirurgi%20i%20Norge.pdf
  4. MacDermid E, Hooton G, MacDonald M, McKay G, Grose D, Mohammed N, et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009;11(3):291-5.
  5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: Cancer Incidence, Mortality and Prevalence Worldwide. CancerBase No. 11, version 1.0 [nettdokument]. Lyon: IARC Press [oppdatert 2013; lest 12.05.2014]. Tilgjengelig fra: http://globocan.iarc.fr
  6. Larsen IK, red. Cancer in Norway 2014: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2014/cin2014-special_issue.pdf
  7. Bray F, Wibe A, Dørum LMR, Møller B. Tykktarms- og endetarmskreft i Norge – epidemiologi. Tidsskr Nor Lægeforen 2007;127(20):2682-7.
  8. Engholm G, Christensen N, Kejs AMT, Johannesen TB, Leinonen MK, Milter MC, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.2 [nettdokument]. København: Association of the Nordic Cancer Registries. Danish Cancer Society [oppdatert 16.12.2015; lest 2016]. Tilgjengelig fra: http://www-dep.iarc.fr/NORDCAN/NO/frame.asp
  9. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: World Cancer Research Fund; American Institute for Cancer Research; 2007. Tilgjengelig fra: http://wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expert-report
  10. Colorectal Cancer 2011 Report: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. Washington DC: World Cancer Research Fund; American Institute for Cancer Research; 2011. Tilgjengelig fra: http://wcrf.org/sites/default/files/Colorectal-Cancer-2011-Report.pdf
  11. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312(6):606-15.
  12. Baglietto L, Jenkins MA, Severi G, Giles GG, Bishop DT, Boyle P, et al. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006;59(2):114-24.
  13. Tranø G, Wasmuth H, Sjursen W, Vatten L. Patient and tumor characteristics may raise clinicians' awareness of familial colorectal cancer: a Norwegian population-based study. Scand J Gastroenterol 2011;46(10):1236-42.
  14. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59(5):666-89.
  15. Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol 2015;12(2):88-97.
  16. Møller P, Stormorken A, Apold J. Arvelig tarmkreft. Tidsskr Nor Lægeforen 2006;126(15):1937-9.
  17. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116(6):1453-6.
  18. Umar A, Boland CR, Terdiman JP, Syngal S, de la CA, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96(4):261-8.
  19. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44(6):353-62.
  20. Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57(5):704-13.
  21. Hansen MF, Johansen J, Bjørnevoll I, Sylvander AE, Steinsbekk KS, Sætrom P, et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam Cancer 2015;14(3):437-48.
  22. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352(18):1851-60.
  23. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62(6):812-23.
  24. De Jong AE, Morreau H, Van Puijenbroek M, Eilers PH, Wijnen J, Nagengast FM, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 2004;126(1):42-8.
  25. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118(5):829-34.
  26. Bulow S. Results of national registration of familial adenomatous polyposis. Gut 2003;52(5):742-6.
  27. Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 2004;12(1):52-8.
  28. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989;2(8666):783-5.
  29. Nielsen M, Hes FJ, Nagengast FM, Weiss MM, Mathus-Vliegen EM, Morreau H, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 2007;71(5):427-33.
  30. Al Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet 2002;30(2):227-32.
  31. Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, Gisbert JP, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 2007;5(3):379-87.
  32. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010;59(7):975-86.
  33. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4(10):769-80.
  34. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61(17):6555-62.
  35. Aziz O, Athanasiou T, Fazio VW, Nicholls RJ, Darzi AW, Church J, et al. Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2006;93(4):407-17.
  36. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378(9809):2081-7.
  37. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50(6):857-60.
  38. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117(16):2104-13.
  39. Lov om humanmedisinsk bruk av bioteknologi m.m. (bioteknologiloven). LOV-2003-12-05-100. Tilgjengelig fra: http://lovdata.no/all/hl-20031205-100.html
  40. Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy 2006;38(3):266-70.
  41. Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol 1986;21(7):853-62.
  42. Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S, et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 1996;39(3):449-56.
  43. Loeve F, Boer R, Zauber AG, Van Ballegooijen M, Van Oortmarssen GJ, Winawer SJ, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111(4):633-9.
  44. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982;49(4):819-25.
  45. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150(1):1-8.
  46. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986;38(2):173-6.
  47. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326(10):658-62.
  48. Lieberman D, Moravec M, Holub J, Michaels L, Eisen G. Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 2008;135(4):1100-5.
  49. IJspeert JE, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol 2015;12(7):401-9.
  50. Holme Ø, Bretthauer M, Eide TJ, Løberg EM, Grzyb K, Løberg M, et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut 2015;64(6):929-36.
  51. Hiraoka S, Kato J, Fujiki S, Kaji E, Morikawa T, Murakami T, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology 2010;139(5):1503-10, 10.e1-3.
  52. Hamilton SR, Aaltonen LA, red. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. World Health Organization classification of tumours 2. Tilgjengelig fra: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/index.php
  53. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-35.
  54. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91(4):854-62.
  55. Jess T, Loftus EV, Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006;130(4):1039-46.
  56. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006;12(3):205-11.
  57. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119(3):647-53.
  58. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2(12):1088-95.
  59. Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120(4):820-6.
  60. Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008;103(9):2342-9.
  61. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53(2):256-60.
  62. Graser A, Stieber P, Nagel D, Schafer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58(2):241-8.
  63. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005;142(8):635-50.
  64. Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349(23):2191-200.
  65. Halligan S, Taylor SA. CT colonography: results and limitations. Eur J Radiol 2007;61(3):400-8.
  66. Ringstad G, Holmquist H, Brabrand K, Aaløkken TM, Hauge T. CT-kolografi for påvisning av kreft og polypper i tykktarm. Tidsskr Nor Lægeforen 2006;126(11):1470-3.
  67. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007;357(22):2277-84.
  68. On the risk to low doses (<100 mSv) of ionizing radiation during medical imaging procedures - IOMP policy statement. J Med Phys 2013;38(2):57-8.
  69. Hendee W. Risk of medical imaging. Med Phys 2013;40(4):040401.
  70. Harewood GC, Wiersema MJ, Melton LJ, III. A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy. Am J Gastroenterol 2002;97(12):3186-94.
  71. Svensson MH, Svensson E, Lasson A, Hellstrom M. Patient acceptance of CT colonography and conventional colonoscopy: prospective comparative study in patients with or suspected of having colorectal disease. Radiology 2002;222(2):337-45.
  72. Johnson KT, Carston MJ, Wentz RJ, Manduca A, Anderson SM, Johnson CD. Development of a cathartic-free colorectal cancer screening test using virtual colonoscopy: a feasibility study. AJR Am J Roentgenol 2007;188(1):W29-W36.
  73. Tan KY, Seow-Choen F, Ng C, Eu KW, Tang CL, Heah SM. Which colorectal cancers are missed by double contrast barium enema? Tech Coloproctol 2004;8(3):169-72.
  74. Ferrucci JT. Double-contrast barium enema: use in practice and implications for CT colonography. AJR Am J Roentgenol 2006;187(1):170-3.
  75. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. Biopsy of colorectal polyps is not adequate for grading of neoplasia. Endoscopy 2005;37(12):1193-7.
  76. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG, red. Gastrointestinal pathology: an atlas and text. Philadelphia: Lippincott-Raven; 1999. s. 961.
  77. Rutter MD, Nickerson C, Rees CJ, Patnick J, Blanks RG. Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme. Endoscopy 2014;46(2):90-7.
  78. Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, et al. Risk factor assessment of endoscopically removed malignant colorectal polyps. Gut 1998;43(5):669-74.
  79. Seitz U, Bohnacker S, Seewald S, Thonke F, Brand B, Braiutigam T, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004;47(11):1789-96.
  80. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89(2):328-36.
  81. Gschwantler M, Kriwanek S, Langner E, Goritzer B, Schrutka-Kolbl C, Brownstone E, et al. High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. Eur J Gastroenterol Hepatol 2002;14(2):183-8.
  82. Hassan C, Zullo A, Winn S, Eramo A, Tomao S, Rossini FP, et al. The colorectal malignant polyp: scoping a dilemma. Dig Liver Dis 2007;39(1):92-100.
  83. Muto T, Sawada T, Sugihara K. Treatment of carcinoma in adenomas. World J Surg 1991;15(1):35-40.
  84. Baatrup G, Endreseth BH, Isaksen V, Kjellmo A, Tveit KM, Nesbakken A. Preoperative staging and treatment options in T1 rectal adenocarcinoma. Acta Oncol 2009;48(3):328-42.
  85. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25(6):657-68.
  86. Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc 2009;69(7):1299-310.
  87. Bloom S, Webster GD. Oxford handbook of gastroenterology and hepatology. Oxford: Oxford University Press; 2006.
  88. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999;94(10):3039-45.
  89. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986;57(9):1866-70.
  90. Edna TH, Karlsen V, Jullumstro E, Lydersen S. Prevalence of anaemia at diagnosis of colorectal cancer: assessment of associated risk factors. Hepatogastroenterology 2012;59(115):713-6.
  91. Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut 2008;57(11):1545-53.
  92. Bjerregaard NC, Tottrup A, Sorensen HT, Laurberg S. Diagnostic value of self-reported symptoms in Danish outpatients referred with symptoms consistent with colorectal cancer. Colorectal Dis 2007;9(5):443-51.
  93. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng K, Marshall T. The risk of colorectal cancer with symptoms at different ages and between the sexes: a case-control study. BMC Med 2009;7:17.
  94. Nesbakken A, Gaard M. Kirurgisk behandling av tykktarmskreft (Surgical treatment of colon cancer). Tidsskr Nor Lægeforen 2007;127(22):2942-5.
  95. Kreftregisteret [nettside]. Oslo: Kreftregisteret [oppdatert 07.12.2009; lest 03.11.2009]. Tilgjengelig fra: http://www.kreftregisteret.no/
  96. Classen M, Tytgat GNJ, Lightdale CJ, red. Gastroenterological endoscopy. Stuttgart; New York: Thieme; 2002.
  97. Dybdahl JH, Daae LN, Larsen S, Myren J. Occult faecal blood loss determined by a 51Cr method and chemical tests in patients referred for colonoscopy. Scand J Gastroenterol 1984;19(2):245-54.
  98. Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269(10):1262-7.
  99. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24(33):5313-27.
  100. Rabeneck L, Rumble RB, Axler J, Smith A, Armstrong D, Vinden C, et al. Cancer Care Ontario Colonoscopy Standards: standards and evidentiary base. Can J Gastroenterol 2007;21 Suppl D:5d-24d.
  101. Dewhurst C, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, et al. ACR Appropriateness Criteria pretreatment staging of colorectal cancer. J Am Coll Radiol 2012;9(11):775-81.
  102. Tudyka V, Blomqvist L, Beets-Tan RG, Boelens PG, Valentini V, van de Velde CJ, et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol 2014;40(4):469-75.
  103. Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer 2007;96(7):1030-6.
  104. Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, et al. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet 2013;381(9873):1194-202.
  105. Neri E, Halligan S, Hellstrom M, Lefere P, Mang T, Regge D, et al. The second ESGAR consensus statement on CT colonography. Eur Radiol 2013;23(3):720-9.
  106. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. Radiology 2011;259(2):393-405.
  107. Burling D. CT colonography standards. Clin Radiol 2010;65(6):474-80.
  108. Halligan S, Altman DG, Taylor SA, Mallett S, Deeks JJ, Bartram CI, et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 2005;237(3):893-904.
  109. radfag.no [nettside]. Oslo: Norsk Radiografforbund [oppdatert 2014; lest 17.11.2014]. Tilgjengelig fra: www.radfag.no
  110. Hansmann A, Burling D. Essential requirements of a CT colonography service. Eur J Radiol 2013;82(8):1187-91.
  111. Pendse DA, Taylor SA. Complications of CT colonography: a review. Eur J Radiol 2013;82(8):1159-65.
  112. Kolfschoten NE, Wouters MW, Gooiker GA, Eddes EH, Kievit J, Tollenaar RA, et al. Nonelective colon cancer resections in elderly patients: results from the dutch surgical colorectal audit. Dig Surg 2012;29(5):412-9.
  113. Gaard M, Drolsum A, Vikil E, V. Y. CT kolografi (CTK) i utredningen av pasienter med koloncancer. Kirurgen 2014;(1):9-11.
  114. Dighe S, Blake H, Koh MD, Swift I, Arnaout A, Temple L, et al. Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg 2010;97(9):1407-15.
  115. Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152-60.
  116. Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, A'Hern R, et al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clin Radiol 2010;65(9):708-19.
  117. Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003;227(2):371-7.
  118. Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 2004;52(1):78-83.
  119. Leufkens AM, van den Bosch MA, van Leeuwen MS, Siersema PD. Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol 2011;46(7-8):887-94.
  120. Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013;17(16):1-243.
  121. Muhi A, Ichikawa T, Motosugi U, Sou H, Nakajima H, Sano K, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011;34(2):326-35.
  122. Lafaro KJ, Roumanis P, Demirjian AN, Lall C, Imagawa DK. Gd-EOB-DTPA-Enhanced MRI for Detection of Liver Metastases from Colorectal Cancer: A Surgeon's Perspective! Int J Hepatol 2013;2013:572307.
  123. Parnaby CN, Bailey W, Balasingam A, Beckert L, Eglinton T, Fife J, et al. Pulmonary staging in colorectal cancer: a review. Colorectal Dis 2012;14(6):660-70.
  124. Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer 2006;94(3):351-7.
  125. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006;333(7572):779.
  126. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012;19(7):2212-23.
  127. Shihab OC, Moran BJ, Heald RJ, Quirke P, Brown G. MRI staging of low rectal cancer. Eur Radiol 2009;19(3):643-50.
  128. Yu SK, Chand M, Tait DM, Brown G. Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. Eur J Cancer 2014;50(5):920-7.
  129. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 2014;50(1):1.e1-1.e34.
  130. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008;95(2):229-36.
  131. Hermanek P, Merkel S, Fietkau R, Rodel C, Hohenberger W. Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TME [corrected] surgery. Implications for treatment decisions. Int J Colorectal Dis 2010;25(3):359-68.
  132. van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013;269(1):101-12.
  133. Patel UB, Brown G. MRI-based assessment of tumor regression in rectal cancer. Curr Colorectal Cancer Rep 2013;9(2):136-45.
  134. Hole KH, Larsen SG, Groholt KK, Giercksky KE, Ree AH. Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer. Radiother Oncol 2013;107(2):178-83.
  135. Akasu T, Kondo H, Moriya Y, Sugihara K, Gotoda T, Fujita S, et al. Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 2000;24(9):1061-8.
  136. Starck M, Bohe M, Simanaitis M, Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers. Colorectal Dis 2003;5(3):246-50.
  137. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology 2004;232(3):773-83.
  138. Kauer WK, Prantl L, Dittler HJ, Siewert JR. The value of endosonographic rectal carcinoma staging in routine diagnostics: a 10-year analysis. Surg Endosc 2004;18(7):1075-8.
  139. Recommendations for cross-sectional imaging in cancer management: computed tomography-CT, magnetic resonance imaging-MRI, positron emission tomography-PET-CT. London: The Royal College of Radiologists; 2006. Tilgjengelig fra: http://www.rcr.ac.uk/docs/oncology/pdf/Cross_Sectional_Imaging_12.pdf
  140. Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006;12(11):1699-705.
  141. Dighe S, Swift I, Brown G. CT staging of colon cancer. Clin Radiol 2008;63(12):1372-9.
  142. Fearon KC, Ljungqvist O, Von Meyenfeldt M, Revhaug A, Dejong CH, Lassen K, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr 2005;24(3):466-77.
  143. Lassen K, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, et al. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg 2009;144(10):961-9.
  144. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations. World J Surg 2013;37(2):259-84.
  145. Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, et al. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr 2012;31(6):801-16.
  146. Lassen K, Hannemann P, Ljungqvist O, Fearon K, Dejong CH, von Meyenfeldt MF, et al. Patterns in current perioperative practice: survey of colorectal surgeons in five northern European countries. BMJ 2005;330(7505):1420-1.
  147. Maessen J, Dejong CH, Hausel J, Nygren J, Lassen K, Andersen J, et al. A protocol is not enough to implement an enhanced recovery programme for colorectal resection. Br J Surg 2007;94(2):224-31.
  148. Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev 2011;(9):CD001544.
  149. Bretagnol F, Panis Y, Rullier E, Rouanet P, Berdah S, Dousset B, et al. Rectal cancer surgery with or without bowel preparation: The French GRECCAR III multicenter single-blinded randomized trial. Ann Surg 2010;252(5):863-8.
  150. Platell C, Barwood N, Makin G. Randomized clinical trial of bowel preparation with a single phosphate enema or polyethylene glycol before elective colorectal surgery. Br J Surg 2006;93(4):427-33.
  151. Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev 2003;(4):CD004423.
  152. Søreide E, Eriksson LI, Hirlekar G, Eriksson H, Henneberg SW, Sandin R, et al. Pre-operative fasting guidelines: an update. Acta Anaesthesiol Scand 2005;49(8):1041-7.
  153. Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Soreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011;28(8):556-69.
  154. Soop M, Nygren J, Myrenfors P, Thorell A, Ljungqvist O. Preoperative oral carbohydrate treatment attenuates immediate postoperative insulin resistance. Am J Physiol Endocrinol Metab 2001;280(4):E576-E83.
  155. Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C, et al. A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. Anesth Analg 2001;93(5):1344-50.
  156. Walker KJ, Smith AF. Premedication for anxiety in adult day surgery. Cochrane Database Syst Rev 2009;(4):CD002192.
  157. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346(13):975-80.
  158. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2009;(1):CD004318.
  159. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994;79(6):1165-77.
  160. Bergqvist D, Lindblad B, Matzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia. Semin Thromb Hemost 1993;19(Suppl 1):147-51.
  161. Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev 2009;(1):CD001181.
  162. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38(12):1706-15.
  163. Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials. Br J Surg 1998;85(9):1232-41.
  164. Kranke P, Eberhart LH. Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. Eur J Anaesthesiol 2011;28(11):758-65.
  165. Uchida I, Asoh T, Shirasaka C, Tsuji H. Effect of epidural analgesia on postoperative insulin resistance as evaluated by insulin clamp technique. Br J Surg 1988;75(6):557-62.
  166. Abdallah FW, Chan VW, Brull R. Transversus abdominis plane block: a systematic review. Reg Anesth Pain Med 2012;37(2):193-209.
  167. Nelson R, Edwards S, Tse B. Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev 2007;(3):CD004929.
  168. Mahoney CB, Odom J. Maintaining intraoperative normothermia: a meta-analysis of outcomes with costs. AANA J 1999;67(2):155-63.
  169. De Witte JL, Demeyer C, Vandemaele E. Resistive-heating or forced-air warming for the prevention of redistribution hypothermia. Anesth Analg 2010;110(3):829-33.
  170. Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet 2002;359(9320):1812-8.
  171. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003;238(5):641-8.
  172. Tambyraja AL, Sengupta F, MacGregor AB, Bartolo DC, Fearon KC. Patterns and clinical outcomes associated with routine intravenous sodium and fluid administration after colorectal resection. World J Surg 2004;28(10):1046-51.
  173. Rahbari NN, Zimmermann JB, Schmidt T, Koch M, Weigand MA, Weitz J. Meta-analysis of standard, restrictive and supplemental fluid administration in colorectal surgery. Br J Surg 2009;96(4):331-41.
  174. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Br J Surg 2006;93(9):1069-76.
  175. Walsh SR, Tang T, Bass S, Gaunt ME. Doppler-guided intra-operative fluid management during major abdominal surgery: systematic review and meta-analysis. Int J Clin Pract 2008;62(3):466-70.
  176. Senagore AJ, Emery T, Luchtefeld M, Kim D, Dujovny N, Hoedema R. Fluid management for laparoscopic colectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program. Dis Colon Rectum 2009;52(12):1935-40.
  177. Holte K, Foss NB, Svensen C, Lund C, Madsen JL, Kehlet H. Epidural anesthesia, hypotension, and changes in intravascular volume. Anesthesiology 2004;100(2):281-6.
  178. Karliczek A, Jesus EC, Matos D, Castro AA, Atallah AN, Wiggers T. Drainage or nondrainage in elective colorectal anastomosis: a systematic review and meta-analysis. Colorectal Dis 2006;8(4):259-65.
  179. Jesus EC, Karliczek A, Matos D, Castro AA, Atallah AN. Prophylactic anastomotic drainage for colorectal surgery. Cochrane Database Syst Rev 2004;(4):CD002100.
  180. Peeters KC, Tollenaar RA, Marijnen CA, Klein KE, Steup WH, Wiggers T, et al. Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. Br J Surg 2005;92(2):211-6.
  181. McPhail MJ, Abu-Hilal M, Johnson CD. A meta-analysis comparing suprapubic and transurethral catheterization for bladder drainage after abdominal surgery. Br J Surg 2006;93(9):1038-44.
  182. Jorgensen H, Wetterslev J, Moiniche S, Dahl JB. Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev 2000;(4):CD001893.
  183. Marret E, Remy C, Bonnet F. Meta-analysis of epidural analgesia versus parenteral opioid analgesia after colorectal surgery. Br J Surg 2007;94(6):665-73.
  184. Basse L, Madsen JL, Kehlet H. Normal gastrointestinal transit after colonic resection using epidural analgesia, enforced oral nutrition and laxative. Br J Surg 2001;88(11):1498-500.
  185. Andersen J, Christensen H, Pachler JH, Hallin M, Thaysen HV, Kehlet H. Effect of the laxative magnesium oxide on gastrointestinal functional recovery in fast-track colonic resection: a double-blind, placebo-controlled randomized study. Colorectal Dis 2012;14(6):776-82.
  186. Tjandra JJ, Chan MK. Systematic review on the short-term outcome of laparoscopic resection for colon and rectosigmoid cancer. Colorectal Dis 2006;8(5):375-88.
  187. Block BM, Liu SS, Rowlingson AJ, Cowan AR, Cowan JA, Jr., Wu CL. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA 2003;290(18):2455-63.
  188. Zutshi M, Delaney CP, Senagore AJ, Mekhail N, Lewis B, Connor JT, et al. Randomized controlled trial comparing the controlled rehabilitation with early ambulation and diet pathway versus the controlled rehabilitation with early ambulation and diet with preemptive epidural anesthesia/analgesia after laparotomy and intestinal resection. Am J Surg 2005;189(3):268-72.
  189. Basse L, Hjort JD, Billesbolle P, Werner M, Kehlet H. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 2000;232(1):51-7.
  190. Cepeda MS, Carr DB, Miranda N, Diaz A, Silva C, Morales O. Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial. Anesthesiology 2005;103(6):1225-32.
  191. Andersen J, Hjort-Jakobsen D, Christiansen PS, Kehlet H. Readmission rates after a planned hospital stay of 2 versus 3 days in fast-track colonic surgery. Br J Surg 2007;94(7):890-3.
  192. Gorissen KJ, Benning D, Berghmans T, Snoeijs MG, Sosef MN, Hulsewe KW, et al. Risk of anastomotic leakage with non-steroidal anti-inflammatory drugs in colorectal surgery. Br J Surg 2012;99(5):721-7.
  193. Andersen HK, Lewis SJ, Thomas S. Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev 2006;(4):CD004080.
  194. Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ 2001;323(7316):773-6.
  195. Han-Geurts IJ, Hop WC, Kok NF, Lim A, Brouwer KJ, Jeekel J. Randomized clinical trial of the impact of early enteral feeding on postoperative ileus and recovery. Br J Surg 2007;94(5):555-61.
  196. Beattie AH, Prach AT, Baxter JP, Pennington CR. A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients. Gut 2000;46(6):813-8.
  197. Keele AM, Bray MJ, Emery PW, Duncan HD, Silk DB. Two phase randomised controlled clinical trial of postoperative oral dietary supplements in surgical patients. Gut 1997;40(3):393-9.
  198. Hyltander A, Bosaeus I, Svedlund J, Liedman B, Hugosson I, Wallengren O, et al. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. Clin Gastroenterol Hepatol 2005;3(5):466-74.
  199. Smedley F, Bowling T, James M, Stokes E, Goodger C, O'Connor O, et al. Randomized clinical trial of the effects of preoperative and postoperative oral nutritional supplements on clinical course and cost of care. Br J Surg 2004;91(8):983-90.
  200. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Am J Surg 2002;183(6):630-41.
  201. Improving outcomes in colorectal cancers: research evidence for the manual update. London: National Institute for Clinical Excellence; 2004.
  202. Nationella riktlinjer för kolorektalcancersjukvård: medicinskt och hälsoekonomiskt faktadokument. Stockholm: Socialstyrelsen; 2007. Tilgjengelig fra: http://www.socialstyrelsen.se/nationellariktlinjerforbrostprostatatjocktarmsochandtarmscancervard
  203. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Fort Washington, PA: National Comprehensive Cancer Network [oppdatert 2009; lest 2009]. Tilgjengelig fra: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (krever registrering)
  204. Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD, Cataldo P, et al. Practice parameters for colon cancer. Dis Colon Rectum 2004;47(8):1269-84.
  205. Hohenberger W, Reingruber B, Merkel S. Surgery for colon cancer. Scand J Surg 2003;92(1):45-52.
  206. Kim JC, Lee KH, Yu CS, Kim HC, Kim JR, Chang HM, et al. The clinicopathological significance of inferior mesenteric lymph node metastasis in colorectal cancer. Eur J Surg Oncol 2004;30(3):271-9.
  207. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23(34):8706-12.
  208. Kelder W, Inberg B, Schaapveld M, Karrenbeld A, Grond J, Wiggers T, et al. Impact of the number of histologically examined lymph nodes on prognosis in colon cancer: a population-based study in the Netherlands. Dis Colon Rectum 2009;52(2):260-7.
  209. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21(15):2912-9.
  210. Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, et al. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg 2008;248(6):968-78.
  211. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009;11(4):354-64.
  212. Smith AJ, Driman DK, Spithoff K, Hunter A, McLeod RS, Simunovic M, et al. Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol 2010;101(5):12.
  213. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008;9(9):857-65.
  214. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010;28(2):272-8.
  215. Croner RS, Merkel S, Papadopoulos T, Schellerer V, Hohenberger W, Goehl J. Multivisceral resection for colon carcinoma. Dis Colon Rectum 2009;52(8):1381-6.
  216. Hunter JA, Ryan JA, Jr., Schultz P. En bloc resection of colon cancer adherent to other organs. Am J Surg 1987;154(1):67-71.
  217. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005;365(9472):1718-26.
  218. Hazebroek EJ. COLOR: a randomized clinical trial comparing laparoscopic and open resection for colon cancer. Surg Endosc 2002;16(6):949-53.
  219.  Kuhry E, Bonjer HJ, Haglind E, Hop WC, Veldkamp R, Cuesta MA, et al. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc 2005;19(5):687-92.
  220. Stormark K, Søreide K, Søreide JA, Kvaløy JT, Pfeffer F, Eriksen MT, et al. Nationwide implementation of laparoscopic surgery for colon cancer: short-term outcomes and long-term survival in a population-based cohort. Surg Endosc 2016;30(11):4853-64.
  221. Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;(2):CD003432.
  222. Jestin P, Nilsson J, Heurgren M, Pahlman L, Glimelius B, Gunnarsson U. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005;92(1):94-100.
  223. McArdle CS, Hole DJ. Emergency presentation of colorectal cancer is associated with poor 5-year survival. Br J Surg 2004;91(5):605-9.
  224. Phillips RK, Hittinger R, Fry JS, Fielding LP. Malignant large bowel obstruction. Br J Surg 1985;72(4):296-302.
  225. Sjo OH, Larsen S, Lunde OC, Nesbakken A. Short term outcome after emergency and elective surgery for colon cancer. Colorectal Dis 2009;11(7):733-9.
  226. Umpleby HC, Williamson RC. Survival in acute obstructing colorectal carcinoma. Dis Colon Rectum 1984;27(5):299-304.
  227. Lee YM, Law WL, Chu KW, Poon RT. Emergency surgery for obstructing colorectal cancers: a comparison between right-sided and left-sided lesions. J Am Coll Surg 2001;192(6):719-25.
  228. Tilney HS, Lovegrove RE, Purkayastha S, Sains PS, Weston-Petrides GK, Darzi AW, et al. Comparison of colonic stenting and open surgery for malignant large bowel obstruction. Surg Endosc 2007;21(2):225-33.
  229. Kube R, Granowski D, Stubs P, Mroczkowski P, Ptok H, Schmidt U, et al. Surgical practices for malignant left colonic obstruction in Germany. Eur J Surg Oncol 2010;36(1):65-71.
  230. Koruth NM, Hunter DC, Krukowski ZH, Matheson NA. Immediate resection in emergency large bowel surgery: a 7 year audit. Br J Surg 1985;72(9):703-7.
  231. Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal Colectomy versus On-table Irrigation and Anastomosis. Br J Surg 1995;82(12):1622-7.
  232. Nesbakken A. Behandling av akutt venstresidig colonobstruksjon. Kirurgen 2014;(1):34-7.
  233. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005;48(12):2264-71.
  234. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008;98(4):277-82.
  235. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92(1):85-91.
  236. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6(8):727-31.
  237. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14(2):484-92.
  238. Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, et al. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei. Eur J Surg Oncol 2012;38(10):969-76.
  239. Dahl O. Adjuvant kjemoterapi ved tykktarmskreft. Tidsskr Nor Lægeforen 2007;127(23):3094-6.
  240. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106(4):899-906.
  241. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005;44(8):904-12.
  242. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345(8955):939-44.
  243. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15(1):246-50.
  244. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22(16):3395-407.
  245. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22(10):1797-806.
  246. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24(13):2059-64.
  247. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, III, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704.
  248. Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 2015;54(1):5-16.
  249. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51.
  250. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 2015;33(35):4176-87.
  251. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29(28):3768-74.
  252. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol 2015;33(32):3733-40.
  253. Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC cancer 2015;15:384.
  254. Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol 2008;19(2):400-2.
  255. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011;305(22):2335-42.
  256. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46(6):1049-55.
  257. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006;107(11):2581-8.
  258. Sun Z, Adam MA, Kim J, Nussbaum DP, Benrashid E, Mantyh CR, et al. Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer. Dis Colon Rectum 2016;59(2):87-93.
  259. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, et al. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer 2013;12(4):275-9.
  260. Peixoto RD, Kumar A, Speers C, Renouf D, Kennecke HF, Lim HJ, et al. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer. Clin Colorectal Cancer 2015;14(1):25-30.
  261. Olsen F, Uleberg B, Jacobsen BK, Balteskard L. Norske pasienter med tykktarmskreft kommer for sent i gang med tilleggsbehandling. Tidsskr Nor Legeforen 2016;136(1):27-31.
  262. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006;24(15):2368-75.
  263. Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev 2010;(1):CD007046.
  264. Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, et al. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Clin Colorectal Cancer 2015;14(4):262-8.e1.
  265. Kim MJ, Jeong SY, Choi SJ, Ryoo SB, Park JW, Park KJ, et al. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol 2015;22(2):505-12.
  266. Edler D, Ohrling K, Hallstrom M, Karlberg M, Ragnhammar P. The number of analyzed lymph nodes - a prognostic factor in colorectal cancer. Acta Oncol 2007;46(7):975-81.
  267. Zhang CD, Wang JN, Sui BQ, Zeng YJ, Chen JQ, Dai DQ. Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy? Medicine 2016;95(1):e2190.
  268. Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi81-8.
  269. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349(3):247-57.
  270. Church DN, Midgley R, Kerr DJ. Stage II colon cancer. Chin Clin Oncol 2013;2(2):16.
  271. Merok MA, Ahlquist T, Royrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013;24(5):1274-82.
  272. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015;33(16):1787-96.
  273. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27(11):1814-21.
  274. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18(23):6531-41.
  275. Zaanan A, Flejou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 2011;17(23):7470-8.
  276. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010;21(4):772-80.
  277. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29(10):1261-70.
  278. Buecher B, Cacheux W, Rouleau E, Dieumegard B, Mitry E, Lievre A. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 2013;45(6):441-9.
  279. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25(23):3456-61.
  280. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27(19):3117-25.
  281. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013;31(3):359-64.
  282. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012;307(13):1383-93.
  283. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25(16):2205-11.
  284. Jakobsen A, Andersen F, Fischer A, Jensen LH, Jorgensen JC, Larsen O, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 2015;54(10):1747-53.
  285. Guidelines for the management of colorectal cancer. London: The Association of Coloproctology of Great Britain & Ireland; 2007.
  286. Danish Colorectal Cancer Group. Retningslinier for diagnostik og behandling af kolorektal cancer: Kirurgisk behandling af cancer recti [nettdokument]. København: Dansk kirurgisk selskab [oppdatert 2010; lest 31.05.2013]. Tilgjengelig fra: http://www.dccg.dk/retningslinjer/indeks.html
  287. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg 1982;69(10):613-6.
  288. Larsen SG, Wiig JN, Emblemsvaag HL, Groholt KK, Hole KH, Bentsen A, et al. Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging. Colorectal Dis 2009;11(7):759-67.
  289.  Lange MM, Buunen M, van de Velde CJ, Lange JF. Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum 2008;51(7):1139-45.
  290. Sato K, Inomata M, Kakisako K, Shiraishi N, Adachi Y, Kitano S. Surgical technique influences bowel function after low anterior resection and sigmoid colectomy. Hepatogastroenterology 2003;50(53):1381-4.
  291. Eriksen MT, Wibe A, Syse A, Haffner J, Wiig JN. Inadvertent perforation during rectal cancer resection in Norway. Br J Surg 2004;91(2):210-6.
  292. Tjandra JJ, Kilkenny JW, Buie WD, Hyman N, Simmang C, Anthony T, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005;48(3):411-23.
  293. Vennix S, Pelzers L, Bouvy N, Beets GL, Pierie JP, Wiggers T, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev 2014;4:Cd005200.
  294. Martel G, Crawford A, Barkun JS, Boushey RP, Ramsay CR, Fergusson DA. Expert opinion on laparoscopic surgery for colorectal cancer parallels evidence from a cumulative meta-analysis of randomized controlled trials. PLoS One 2012;7(4):e35292.
  295. Diana M, Marescaux J. Robotic surgery. Br J Surg 2015;102(2):e15-28.
  296. Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, et al. Transanal Total Mesorectal Excision for Rectal Cancer: Outcomes after 140 Patients. J Am Coll Surg 2015;221(2):415-23.
  297. Araujo SE, Crawshaw B, Mendes CR, Delaney CP. Transanal total mesorectal excision: a systematic review of the experimental and clinical evidence. Tech Coloproctol 2015;19(2):69-82.
  298. Hompes R, Arnold S, Warusavitarne J. Towards the safe introduction of transanal total mesorectal excision: the role of a clinical registry. Colorectal Dis 2014;16(7):498-501.
  299. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008;(2):CD006040.
  300. Ooi BS, Lai JH. Colonic J-Pouch, Coloplasty, Side-to-End Anastomosis: Meta-Analysis and Comparison of Outcomes. Seminars in Colon and Rectal Surgery 2009;20(2):69-72.
  301. Edwards DP, Sexton R, Heald RJ, Moran BJ. Long-term results show triple stapling facilitates safe low colorectal and coloanal anastomosis and is associated with low rates of local recurrence after anterior resection for rectal cancer. Tech Coloproctol 2007;11(1):17-21.
  302. Terzi C, Unek T, Sagol O, Yilmaz T, Fuzun M, Sokmen S, et al. Is rectal washout necessary in anterior resection for rectal cancer? A prospective clinical study. World J Surg 2006;30(2):233-41.
  303. Matthiessen P, Hallbook O, Rutegard J, Sjodahl R. Population-based study of risk factors for postoperative death after anterior resection of the rectum. Br J Surg 2006;93(4):498-503.
  304. Huser N, Michalski CW, Erkan M, Schuster T, Rosenberg R, Kleeff J, et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg 2008;248(1):52-60.
  305. Tan WS, Tang CL, Shi L, Eu KW. Meta-analysis of defunctioning stomas in low anterior resection for rectal cancer. Br J Surg 2009;96(5):462-72.
  306. Eriksen MT, Wibe A, Norstein J, Haffner J, Wiig JN. Anastomotic leakage following routine mesorectal excision for rectal cancer in a national cohort of patients. Colorectal Dis 2005;7(1):51-7.
  307. Chen J, Zhang Y, Jiang C, Yu H, Zhang K, Zhang M, et al. Temporary ileostomy versus colostomy for colorectal anastomosis: evidence from 12 studies. Scand J Gastroenterol 2013;48(5):556-62.
  308. Jafari MD, Halabi WJ, Jafari F, Nguyen VQ, Stamos MJ, Carmichael JC, et al. Morbidity of diverting ileostomy for rectal cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program. Am Surg 2013;79(10):1034-9.
  309. Jonker FH, Tanis PJ, Coene PP, van der Harst E. Impact of Neoadjuvant Radiotherapy on Complications After Hartmann Procedure for Rectal Cancer. Dis Colon Rectum 2015;58(10):931-7.
  310.  Mandava N, Kumar S, Pizzi WF, Aprile IJ. Perforated colorectal carcinomas. Am J Surg 1996;172(3):236-8.
  311. Holm T, Ljung A, Häggmark T, Jurell G, Lagergren J. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg 2007;94(2):232-8.
  312. Prytz M, Angenete E, Ekelund J, Haglind E. Extralevator abdominoperineal excision (ELAPE) for rectal cancer--short-term results from the Swedish Colorectal Cancer Registry. Selective use of ELAPE warranted. Int J Colorectal Dis 2014;29(8):981-7.
  313. Tytherleigh MG, Warren BF, Mortensen NJ. Management of early rectal cancer. Br J Surg 2008;95(4):409-23.
  314. Borschitz T, Heintz A, Junginger T. The influence of histopathologic criteria on the long-term prognosis of locally excised pT1 rectal carcinomas: results of local excision (transanal endoscopic microsurgery) and immediate reoperation. Dis Colon Rectum 2006;49(10):1492-506.
  315. Borschitz T, Gockel I, Kiesslich R, Junginger T. Oncological outcome after local excision of rectal carcinomas. Ann Surg Oncol 2008;15(11):3101-8.
  316. Bouvet M, Milas M, Giacco GG, Cleary KR, Janjan NA, Skibber JM. Predictors of recurrence after local excision and postoperative chemoradiation therapy of adenocarcinoma of the rectum. Ann Surg Oncol 1999;6(1):26-32.
  317. Le Voyer TE, Hoffman JP, Cooper H, Ross E, Sigurdson E, Eisenberg B. Local excision and chemoradiation for low rectal T1 and T2 cancers is an effective treatment. Am Surg 1999;65(7):625-30.
  318. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg 2008;95(1):33-49.
  319. Moriya Y, Hojo K, Sawada T, Koyama Y. Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum 1989;32(4):307-15.
  320. Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006;49(11):1663-72.
  321. Takahashi T, Ueno M, Azekura K, Ohta H. Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum 2000;43(10 Suppl):S59-S68.
  322. Shihab OC, Taylor F, Bees N, Blake H, Jeyadevan N, Bleehen R, et al. Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. Br J Surg 2011;98(12):1798-804.
  323. Kusters M, Marijnen CA, van de Velde CJ, Rutten HJ, Lahaye MJ, Kim JH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 2010;36(5):470-6.
  324. Kusters M, Beets GL, van de Velde CJ, Beets-Tan RG, Marijnen CA, Rutten HJ, et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg 2009;249(2):229-35.
  325. Georgiou P, Tan E, Gouvas N, Antoniou A, Brown G, Nicholls RJ, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol 2009;10(11):1053-62.
  326. Cheng H, Deng Z, Wang ZJ, Zhang W, Su JT. Lateral lymph node dissection with radical surgery versus single radical surgery for rectal cancer: a meta-analysis. Asian Pac J Cancer Prev 2011;12(10):2517-21.
  327. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345(9):638-46.
  328. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336(14):980-7.
  329. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575-82.
  330. Brændengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008;26(22):3687-94.
  331. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42(5-6):476-92.
  332. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol 2007;46(4):504-16.
  333. Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, et al. Late Side Effects and Quality of Life After Radiotherapy for Rectal Cancer. Int J Radiat Oncol Biol Phys 2010;76(4):1005-11.
  334. Pietrzak L, Bujko K, Nowacki MP, Kepka L, Oledzki J, Rutkowski A, et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. Radiother Oncol 2007;84(3):217-25.
  335. Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund A, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. Int J Radiat Oncol Biol Phys 2011;81(4):1017-24.
  336. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811-20.
  337. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30(16):1926-33.
  338. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009;92(2):148-63.
  339. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26(2):303-12.
  340. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89(3):327-34.
  341. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011;98(6):872-9.
  342. Bernstein TE, Endreseth BH, Romundstad P, Wibe A. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009;96(11):1348-57.
  343. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26(3):350-7.
  344. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, et al. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 2008;19(Suppl 6):vi1-vi8.
  345. Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer PJ, Sr. Role of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol 2011;29(22):3097-102.
  346. Ceelen W, Fierens K, Van Nieuwenhove Y, Pattyn P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer 2009;124(12):2966-72.
  347. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24(4):668-74.
  348. Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kahler G, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006;66(5):1384-90.
  349. Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC cancer 2013;13:279.
  350. Bjerkeset T, Morild I, Mørk S, Søreide O. Tumor characteristics in colorectal cancer and their relationship to treatment and prognosis. Dis Colon Rectum 1987;30(12):934-8.
  351. Frykholm GJ, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001;50(2):427-34.
  352. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620-5.
  353. Rominger CJ, Gunderson LL, Gelber RD, Conner N. Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16). Am J Clin Oncol 1985;8(2):118-27.
  354. Radu C, Berglund A, Pahlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 2008;87(3):343-9.
  355. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009;92(2):210-4.
  356. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013;24(7):1762-9.
  357. Schmoll HJ, Van CE, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012;23(10):2479-516.
  358. Dahl O, Horn A, Morild I, Halvorsen JF, Odland G, Reinertsen S, et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway. Cancer 1990;66(11):2286-94.
  359. Tveit KM, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg 1997;84(8):1130-5.
  360. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324(11):709-15.
  361. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004;22(3):484-92.
  362. Group QC, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370(9604):2020-9.
  363. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15(2):184-90.
  364. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997;40(1):35-41.
  365. Valentini V, Glimelius B, Haustermans K, Marijnen CA, Rodel C, Gambacorta MA, et al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review. Radiother Oncol 2014;110(1):195-8.
  366. Cameron MG, Kersten C, Vistad I, Fossa S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. Acta Oncol 2014;53(2):164-73.
  367. Nielsen M, Rasmussen P, Pedersen B, Hagemann-Madsen R, Lindegaard J, Laurberg S. Early and Late Outcomes of Surgery for Locally Recurrent Rectal Cancer: A Prospective 10-Year Study in the Total Mesorectal Excision Era. Ann Surg Oncol 2015;22(8):2677-84.
  368. Gunderson LL, Haddock MG, Nelson H, Cha S, Devine RM, Fieck JM, et al. Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection. Front Radiat Ther Oncol 1997;31:224-8.
  369. Troja A, El-Sourani N, Abdou A, Antolovic D, Raab HR. Surgical options for locally recurrent rectal cancer--review and update. Int J Colorectal Dis 2015;30(9):1157-63.
  370. Hansen MH, Balteskard L, Dørum LMR, Eriksen MT, Vonen B, Group NCC. Locally recurrent rectal cancer in Norway. Br J Surg 2009;96(10):1176-82.
  371. Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002;95(5):1144-50.
  372. Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys 2006;64(4):1129-39.
  373. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010;77(1):60-5.
  374. Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 2014;113(2):151-7.
  375. Ng MK, Leong T, Heriot AG, Ngan SY. Once-daily reirradiation for rectal cancer in patients who have received previous pelvic radiotherapy. J Med Imaging Radiat Oncol 2013;57(4):512-8.
  376. Lev-Chelouche D, Keidar A, Rub R, Matzkin H, Gutman M. Hydronephrosis associated with colorectal carcinoma: treatment and outcome. Eur J Surg Oncol 2001;27(5):482-6.
  377. Lopez MJ, Kraybill WG, Downey RS, Johnston WD, Bricker EM. Exenterative surgery for locally advanced rectosigmoid cancers. Is it worthwhile? Surgery 1987;102(4):644-51.
  378. Larsen SG, Wiig JN, Giercksky KE. Hydronephrosis as a prognostic factor in pelvic recurrence from rectal and colon carcinomas. Am J Surg 2005;190(1):55-60.
  379. Tanis PJ, Doeksen A, van Lanschot JJ. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013;56(2):135-44.
  380. Wiig JN, Larsen SG, Dueland S, Giercksky KE. Preoperative irradiation and surgery for local recurrence of rectal and rectosigmoid cancer. Prognostic factors with regard to survival and further local recurrence. Colorectal Dis 2008;10(1):48-57.
  381. Wanebo HJ, Gaker DL, Whitehill R, Morgan RF, Constable WC. Pelvic recurrence of rectal cancer. Options for curative resection. Ann Surg 1987;205(5):482-95.
  382. Søreide JA, Eiriksson K, Sandvik O, Viste A, Horn A, Johnsen G, et al. Kirurgisk behandling av levermetastaser fra kolorektal kreft. Tidsskr Nor Lægeforen 2008;128(1):50-3.
  383. Bonanni L, De'liguori Carino N, Deshpande R, Ammori BJ, Sherlock DJ, Valle JW, et al. A comparison of diagnostic imaging modalities for colorectal liver metastases. Eur J Surg Oncol 2014;40(5):545-50.
  384. Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg 2014;259(5):861-72.
  385. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240(6):1027-34.
  386. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104(12):2658-70.
  387. Group. CCC. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358(9290):1291-304.
  388. Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 2005;92(9):1165-8.
  389. Higgins H, Berger DL. RFA for liver tumors: does it really work? Oncologist 2006;11(7):801-8.
  390. Ko S, Jo H, Yun S, Park E, Kim S, Seo HI. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol 2014;20(2):525-31.
  391. Stoltz A, Gagniere J, Dupre A, Rivoire M. Radiofrequency ablation for colorectal liver metastases. J Visc Surg 2014;151 Suppl 1:S33-44.
  392. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014;50(5):912-9.
  393. Brudvik KW, Bains SJ, Seeberg LT, Labori KJ, Waage A, Tasken K, et al. Aggressive treatment of patients with metastatic colorectal cancer increases survival: a scandinavian single-center experience. HPB Surg 2013;2013:727095.
  394. Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 2013;100(6):808-18.
  395. Thelen A, Jonas S, Benckert C, Schumacher G, Lopez-Hanninen E, Rudolph B, et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007;33(3):324-8.
  396. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371(9617):1007-16.
  397. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2012;255(3):534-9.
  398. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14(12):1208-15.
  399. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18(1):15-24.
  400. Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007;204(5):753-61.
  401. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24(31):4976-82.
  402. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240(4):644-57.
  403. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012;11(3):155-66.
  404. Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014;50(9):1590-601.
  405. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008;19(5):909-14.
  406. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30(15):1755-62.
  407. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014;25(5):1018-25.
  408. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371(17):1609-18.
  409. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11(9):845-52.
  410. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg 2007;94(2):129-31.
  411. Corrin B, Nicholson AG. Pathology of the lungs. Philadelphia: Churchill Livingstone; 2006.
  412. Shirouzu K, Isomoto H, Hayashi A, Nagamatsu Y, Kakegawa T. Surgical treatment for patients with pulmonary metastases after resection of primary colorectal carcinoma. Cancer 1995;76(3):393-8.
  413. Internullo E, Cassivi SD, Van Raemdonck D, Friedel G, Treasure T. Pulmonary metastasectomy: a survey of current practice amongst members of the European Society of Thoracic Surgeons. J Thorac Oncol 2008;3(11):1257-66.
  414. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992;127(12):1403-6.
  415. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007;84(1):324-38.
  416. Avital I, DeMatteo R. Combined resection of liver and lung metastases for colorectal cancer. Thorac Surg Clin 2006;16(2):145-55, vi.
  417. Barlow AD, Nakas A, Pattenden C, Martin-Ucar AE, Dennison AR, Berry DP, et al. Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases. Eur J Surg Oncol 2009;35(3):307-12.
  418. Tanaka Y, Maniwa Y, Nishio W, Yoshimura M, Okita Y. The optimal timing to resect pulmonary metastasis. Eur J Cardiothorac Surg 2008;33(6):1135-8.
  419. Fanucchi O, Ambrogi MC, Aprile V, Cioni R, Cappelli C, Melfi F, et al. Long-term results of percutaneous radiofrequency ablation of pulmonary metastases: a single institution experience. Interact Cardiovasc Thorac Surg 2016;23(1):57-64.
  420. Macbeth F, Treasure T. Stereotactic Ablative Radiotherapy for 'Oligometastases': a Treatment in Search of Evidence. Clin Oncol (R Coll Radiol) 2016;28(8):501-2.
  421. Blackmon SH, Stephens EH, Correa AM, Hofstetter W, Kim MP, Mehran RJ, et al. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg 2012;94(6):1802-9.
  422. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013;20(2):572-9.
  423. Treasure T, Fallowfield L, Farewell V, Ferry D, Lees B, Leonard P, et al. Pulmonary metastasectomy in colorectal cancer: time for a trial. Eur J Surg Oncol 2009;35(7):686-9.
  424.  Chua TC, Morris DL. Therapeutic potential of surgery for metastatic colorectal cancer. Scand J Gastroenterol 2012;47(3):258-68.
  425. Gonzalez M, Ris HB, Krueger T, Gervaz P. Colorectal cancer and thoracic surgeons: close encounters of the third kind. Expert Rev Anticancer Ther 2012;12(4):495-503.
  426. Sugarbaker PH. Carcinomatosis--is cure an option? J Clin Oncol 2003;21(5):762-4.
  427. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12(1):65-71.
  428. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128(11):2717-25.
  429. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89(12):1545-50.
  430. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15(9):2426-32.
  431. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27(5):681-5.
  432. Elias D, Raynard B, Farkhondeh F, Goere D, Rouquie D, Ciuchendea R, et al. Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol 2006;30(10):1200-4.
  433. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De SM, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22(16):3284-92.
  434. Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 2008;248(5):829-35.
  435. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, III, et al. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 2008;15(11):3065-72.
  436. Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 2010;101(8):713-24.
  437. van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003;12(3):771-80.
  438. Elias D, Goere D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008;247(3):445-50.
  439. Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol 2009;35(2):164-7.
  440. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 2012;8:CD008997.
  441. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27(20):3379-84.
  442. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001;88(10):1352-6.
  443. Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, et al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 2015;51(2):166-76.
  444. Wilkinson KJ, Chua W, Ng W, Roohullah A. Management of asymptomatic primary tumours in stage IV colorectal cancer: Review of outcomes. World J Gastrointest Oncol 2015;7(12):513-23.
  445. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115(20):4679-87.
  446. Glimelius B, Cavalli-Bjorkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol 2012;47(3):296-314.
  447. Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013;24(9):2354-60.
  448. Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012;38(6):618-25.
  449. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100(2):266-73.
  450. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372(26):2509-20.
  451. Sørbye H, Brændengen M, Balteskard L. Palliativ kjemoterapi og strålebehandling ved metastatisk kolorektal cancer. Tidsskr Nor Lægeforen 2008;128(2):194-7.
  452. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003;361(9356):457-64.
  453. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27(34):5727-33.
  454. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007;25(22):3224-9.
  455. Grothey A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology 2010;79(5-6):389-99.
  456. Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12(11):1032-44.
  457. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370(9582):135-42.
  458. Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. [Foredrag på 2009 ASCO Annual Meeting]. J Clin Oncol 2009;27(15 Suppl):4024.
  459. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370(9582):143-52.
  460. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47.
  461. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-7.
  462. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13(12):1868-73.
  463. Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22(1):31-8.
  464. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37.
  465. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26(12):2006-12.
  466. Leo S, Accettura C, Gnoni A, Licchetta A, Giampaglia M, Mauro A, et al. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer 2013;44(1):22-32.
  467. Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol 2012;9(12):716-25.
  468. Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012;51(7):831-9.
  469. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30):4779-86.
  470. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42.
  471. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-12.
  472. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14(9):862-70.
  473. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-9.
  474. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20(11):1842-7.
  475. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van CE, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37.
  476. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14(11):1077-85.
  477. Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011;104(3):413-8.
  478. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34.
  479. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9.
  480. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64.
  481. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34.
  482. Bokemeyer C, Bondarenko I, Hartmann JT, de BF, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46.
  483. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
  484. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-705.
  485. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103-14.
  486. Ku GY, Haaland BA, de Lima Lopes G, Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 2012;70(2):231-8.
  487. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25(34):5390-6.
  488. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013;24(8):2062-7.
  489. Sorbye H, Berglund A, Tveit KM, Ogreid D, Wanderas EH, Wentzel-Larsen T, et al. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007;46(7):982-8.
  490. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44.
  491. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706-13.
  492. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-9.
  493. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65.
  494. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15(6):569-79.
  495. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12.
  496. WHO Definition of Palliative CareGeneva: World Health Organization [oppdatert 2010; lest 16.12.2009]. Tilgjengelig fra: http://www.who.int/cancer/palliative/definition/en/
  497. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. rev utg. Oslo: Helsedirektoratet; 2013. IS-2101. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen-/Publikasjoner/nasjonalt-handlingsprogram-for-palliasjon-i-kreftomsorgen.pdf
  498. Hannon B, Zimmermann C. Early palliative care: moving from 'why' to 'how'. Oncology (Williston Park, NY) 2013;27(1).
  499. Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol 2013;5(6):318-23.
  500. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383(9930):1721-30.
  501. Breitenstein S, Rickenbacher A, Berdajs D, Puhan M, Clavien PA, Demartines N. Systematic evaluation of surgical strategies for acute malignant left-sided colonic obstruction. Br J Surg 2007;94(12):1451-60.
  502. Dormann A, Meisner S, Verin N, Wenk LA. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy 2004;36(6):543-50.
  503. Jeurnink SM, Steyerberg EW, Hof G, van Eijck CH, Kuipers EJ, Siersema PD. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. J Surg Oncol 2007;96(5):389-96.
  504. Moss AC, Morris E, Mac MP. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006;(2):CD004200.
  505. Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol 2004;99(10):2051-7.
  506. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. Ann Surg 2007;246(1):24-30.
  507. Spinelli P, Calarco G, Mancini A, Ni XG. Operative colonoscopy in cancer patients. Minim Invasive Ther Allied Technol 2006;15(6):339-47.
  508. Meyer L, Pothuri B. Decompressive percutaneous gastrostomy tube use in gynecologic malignancies. Curr Treat Options Oncol 2006;7(2):111-20.
  509. Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005;96(2):330-4.
  510. van Delden OM, Laméris JS. Percutaneous drainage and stenting for palliation of malignant bile duct obstruction. Eur Radiol 2008;18(3):448-56.
  511. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45(10):1748-56.
  512. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009;(1):CD006041.
  513. Nieder C, Pawinki A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology 2009;76(5):369-74.
  514. Roswit B, Malsky SJ, Reid CB. Severe radiation injuries of the stomach, small intestine, colon and rectum. Am J Roentgenol Radium Ther Nucl Med 1972;114(3):460-75.
  515. Spanos WJJ, Wasserman T, Meoz R, Sala J, Kong J, Stetz J. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study. Int J Radiat Oncol Biol Phys 1987;13(10):1479-82.
  516. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5(2):108-13.
  517. Amichetti M, Lay G, Dessì M, Orrù S, Farigu R, Orrù P, et al. Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori 2005;91(2):163-7.
  518. Cameron M, Kersten C, van Helvoirt R. Outcomes of Whole Brain Radiation Therapy for Metastatic Disease: A Retrospective Population-Based Cohort Analysis. Foredrag på the Eighth Congress of the European Association for Neuro-Oncology (EANO), September 12-14, 2008 Barcelona, Spain. Neuro Oncol 2010;10(6):1116 (P139).
  519. Rades D, Dahm-Daphi J, Rudat V, Schulte R, Stalpers LJ, Veninga T, et al. Is short-course radiotherapy with high doses per fraction the appropriate regimen for metastatic spinal cord compression in colorectal cancer patients? Strahlenther Onkol 2006;182(12):708-12.
  520. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012;24(2):112-24.
  521. Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15(2):164-71.
  522. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993;27(1):117-23.
  523. Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 1981;7(5):587-91.
  524. McArdle C. ABC of colorectal cancer: effectiveness of follow up. BMJ 2000;321(7272):1332-5.
  525. Northover J. Realism or nihilism in bowel cancer follow-up? Lancet 1998;351(9109):1074-6.
  526. Tappenden P, Chilcott J, Brennan A, Pilgrim H. Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom. Int J Technol Assess Health Care 2009;25(4):470-8.
  527. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007;(1):CD002200.
  528. Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol 2016;27(2):274-80.
  529. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014;311(3):263-70.
  530. Bouvier AM, Latournerie M, Jooste V, Lepage C, Cottet V, Faivre J. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer 2008;44(4):522-7.
  531. Cali RL, Pitsch RM, Thorson AG, Watson P, Tapia P, Blatchford GJ, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993;36(4):388-93.
  532. Norum J, Gerner T, Bergan A, Lange O. Kontrollopplegg etter potensiell kurativ operasjon for kolorektalcancer. Anbefaling fra Norsk Gastrointestinal Cancer Gruppe. Tidsskr Nor Lægeforen 1997;117(20):2965-8.
  533. Bregendahl S, Emmertsen KJ, Lous J, Laurberg S. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis 2013;15(9):1130-9.
  534. Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 2012;255(5):922-8.
  535. Newell KJ, Sawka BW, Rudrick BF, Driman DK. GEWF solution. Arch Pathol Lab Med 2001;125(5):642-5.
  536.  Sobin LH, Wittekind C, Gospodarwicz MK, red. TNM : classification of malignant tumours. 7 utg. Oxford: Wiley-Blackwell; 2010.
  537. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4.
  538. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66.
  539. Bentzen SM, Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Sorensen F, Bone J, et al. Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. Br J Cancer 1992;65(1):102-7.
  540. Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012;118(3):628-38.
  541. Haugland HK, Casati B, Dorum LM, Bjugn R. Template reporting matters--a nationwide study on histopathology reporting on colorectal carcinoma resections. Hum Pathol 2011;42(1):36-40.
  542. Koren R, Siegal A, Klein B, Halpern M, Kyzer S, Veltman V, et al. Lymph node-revealing solution: simple new method for detecting minute lymph nodes in colon carcinoma. Dis Colon Rectum 1997;40(4):407-10.
  543. Al Sahaf O, Myers E, Jawad M, Browne TJ, Winter DC, Redmond HP. The prognostic significance of extramural deposits and extracapsular lymph node invasion in colon cancer. Dis Colon Rectum 2011;54(8):982-8.
  544. Suzuki H, Fujii T, Asao T, Tsutsumi S, Wada S, Araki K, et al. Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. World J Surg 2014;38(8):2079-88.
  545. Bjugn R, Dirdal HU. Kolorektalcancer--erfaringer med bruk av maler for rapportering av patologisk-anatomiske data. Tidsskr Nor Lægeforen 2001;121(14):1697-701.
  546. Bateman AC, Jaynes E, Bateman AR. Rectal cancer staging post neoadjuvant therapy--how should the changes be assessed? Histopathology 2009;54(6):713-21.
  547. Veileder i biopsibesvarelse av maligne svulster. 2 utg. Oslo: Den norske legeforening; 2012. Skriftserie for leger: Utdanning og kvalitetsutvikling.
  548. Rothenberger DA, Garcia-Aguilar J. Management of cancer in a polyp. I: Saltz LB, red. Colorectal cancer: multimodality management. Totowa, N.J.: Humana; 2002. s. 325-35.
  549. Premaligne polypper og tidlig-cancer i rektum [nettside]. Norwegian Gastrointestinal Cancer Group [oppdatert 11.04.2011; lest 01.08.2011].
  550. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27(10):1579-84.
  551. Adam R, Registry ELT. Data Analysis Booklet 05/68-12/01. Villejuif Cedex: European Liver Transplant Registry (ELTR); 2009.
  552. Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013;257(5):800-6.
  553. Generelt om klinisk utprøving av legemidlerOslo: Legemiddelverket [oppdatert 2009; lest 09.12.2009]. Tilgjengelig fra: www.legemiddelverket.no
  554. Stein GE. Regulated drug development and usage. I: Brody TM, Larner J, Wecker L, Minneman KP, red. Brody's human pharmacology: molecular to clinical. Philadelphia: Elsevier Mosby; 2005. s. 71-5.
  555. Nasjonal helseplan (2007-2010). Særtrykk av St.prp. nr.1 (2006-2007) kapittel 6. Oslo: Helse- og omsorgsdepartementet; 2009. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf
  556. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30.
  557. Glimelius B, Jakobsen A, Graf W, Berglund A, Gadeberg C, Hansen P, et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 1998;34(5):674-8.
  558. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10(6):904-11.
  559. Andre T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007;18(1):77-81.
  560. Sobin LH, Gospodarowicz M, Wittekind C, red. TNM: classification of malignant tumors. 7 utg. Oxford: Wiley-Blackwell; 2010.
  561. Nagtegaal ID, van Krieken JH. The role of pathologists in the quality control of diagnosis and treatment of rectal cancer-an overview. Eur J Cancer 2002;38(7):964-72.